Primary Products

Beginning with cases diagnosed in January 1, 2024 and forward, the Cancer PathCHART initiative standards included in the Cancer PathCHART ICD-O-3 Site Morphology Validation Lists (CPC SMVLs) should be used.

  • These lists designate all tumor site-morphology combinations that are either valid or impossible as determined for the sites reviewed by the Cancer PathCHART initiative.
  • For sites not yet reviewed by Cancer PathCHART, the existing standards from 2023 will remain unchanged in these lists.
  • For cases diagnosed January 1, 2024, and forward, the CPC SMVLs serve as the basis for the Primary Site, Morphology-Type, Beh ICDO3 2024 (N7040) edit, which checks for valid, unlikely and impossible site, histology, and behavior code combinations.

Standards Released Fall 2025

For the 2024 and 2025 CPC SMVLs, second versions (V2024A and V2025A) are included in the current October 2025 release file along with the 2026 standards (V2026) as separate columns for each implementation year. This version, released in October 2025, is V2024A_V2025A_V2026. Details about changes to CPC SMVL file generation can be found in the V2024A_V2025A_V2026 CPC SMVL Release Notes (DOCX, 42 KB). Head and neck sites were the only primary tumor sites reviewed for the V2026 CPC SMVL.

Archived Tumor Site-Morphology Standards

The most current standards for cases diagnosed 2024 through 2026 are posted above. Users are highly encouraged to use the updated standards above. To receive the archived CPC SMVL files that are out of date, email ncicancerpathchart@mail.nih.gov.

Sites Reviewed by Implementation Year

Tumor Sites Not Yet Reviewed

Organ System Primary Tumor Site(s)
Pending Sites Skin, Eye and Orbit, Thyroid Gland, Adrenal Gland, Pituitary, Craniopharyngeal Duct, Pineal Gland, Parathyroid Gland, Carotid body, Aortic Body and Other Paraganglia

2026

Organ System Primary Tumor Site(s)
Head and Neck Lip, Oral Cavity and Mobile Tongue, Gingiva, Major Salivary Glands, Nasopharynx, Oropharynx, Branchial cleft, Nasal Cavity and Paranasal Sinuses, Middle Ear, Larynx and Hypopharynx, Pharynx including Waldeyer Ring, Trachea and Upper Respiratory

2025

Organ System Primary Tumor Site(s)
Respiratory Tract Lung and Bronchus; Pleura
Thorax Thymus; Mediastinal Space
Soft Tissue Peripheral Nerves and Autonomic Nervous System; Retroperitoneum; Heart and Pericardium
Male Genital System Epididymis, Paratesticular and Spermatic cord; Testis*
Urinary System Urethra; Urothelial Sites; Paraurethral Gland; Kidney*
CNS Cerebral Hemispheres; Cerebellum; Brainstem; Ventricles; Meninges; Cranial Nerves; Spinal Cord

2024

Organ System Primary Tumor Site(s)
Bone & Soft Tissue Bones & Joints; Connective, Subcutaneous & Other Soft Tissue
Breast Breast
Digestive Ampulla of Vater; Anus; Appendix; Biliary System; Colon & Rectum; Esophagus; Gallbladder; Liver; Pancreas; Small Intestine; Stomach
Female Genital Cervix; Endometrium; Fallopian Tube; Myometrium; Ovary; Vagina; Vulva, Adnexa & Other Female Genital; Placenta
Male Genital Penis; Prostate; Testis*
Urinary Kidney*

* Morphologies not reviewed for the tumor site for implementation in 2024 were reviewed for implementation in 2025.

CPC*Search Tool

Magnifying Glass Search Icon

This Search Interface for 2024 allows for searches of histology and behavior codes, morphology terms, and tumor site combinations in the 2024 CPC SMVL.

Visit Now

Future Plans

A webtool is planned for a future calendar year. It will allow searches of

  • Valid tumor morphologies at a given cancer site
  • Valid tumor sites for a given cancer morphology
  • Related terminology for a given histology term
  • Mapping of histology terminology across standards
  • Mapping of terminology and codes across versions of tumor entities